FDA Approves Strattera(R) For Maintenance Of ADHD In Children And Adolescents
May 15th 2008Drug InformationADHD
Eli Lilly and Company (NYSE: LLY) announced that the United States Food and Drug Administration (FDA) has approved Strattera(R) (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
